Circulating Tumor DNA and Circulating Tumor Cells for Cancer Management (Liquid Biopsy)
ثبت نشده
چکیده
©2017 Blue Cross and Blue Shield of Louisiana An independent licensee of the Blue Cross and Blue Shield Association No part of this publication may be reproduced, stored in a retrieval system, or transmitted, in any form or by any means, electronic, mechanical, photocopying, or otherwise, without permission from Blue Cross and Blue Shield of Louisiana. Page 1 of 14 Applies to all products administered or underwritten by Blue Cross and Blue Shield of Louisiana and its subsidiary, HMO Louisiana, Inc.(collectively referred to as the “Company”), unless otherwise provided in the applicable contract. Medical technology is constantly evolving, and we reserve the right to review and update Medical Policy periodically.
منابع مشابه
Liquid Biopsy as a Minimally Invasive Source of Thyroid Cancer Genetic and Epigenetic Alterations
In the blood of cancer patients, some nucleic acid fragments and tumor cells can be found that make it possible to trace tumor changes through a simple blood test called “liquid biopsy”. The main components of liquid biopsy are fragments of DNA and RNA shed by tumors into the bloodstream and circulate freely( ctDNAs and ctRNAs). tumor cells which are shed into the blood (circulating tumor cells...
متن کاملMedical Policy Policy Title Circulating Tumor Dna and Circulating Tumor Cells for Cancer Management (liquid Biopsy) [formerly Detection of Circulating Tumor Cells in the Management of Patients
The use of circulating tumor DNA and circulating tumor cells is considered investigational and therefore not covered for all indications. There is insufficient evidence to support a conclusion concerning the health outcomes or benefits associated with this procedure. Cross-reference: MP-2.235 Assays of Genetic Expression in Tumor Tissue as a Technique to Determine Prognosis in Patients with Bre...
متن کامل